The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn

References

• Zaheer S, LeBoff M, Lewiecki EM. Denosumab for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol. 2015;11(3):461–470.
   PubMed Web of Science ®Google Scholar
• Prolia approval history. Accessed Feb 2020. Available from: https://www.drugs.com/history/prolia.html
   Google Scholar
• Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473(2):139–146.
   PubMed Web of Science ®Google Scholar
• Galvano A, Scaturro D, Badalamenti G, et al. Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials. J Bone Oncol. 2019;18:100252.
   PubMed Web of Science ®Google Scholar
• Peters S, Clézardin P, Márquez-Rodas I, et al. The RANK-RANKL axis: an opportunity for drug repurposing in cancer? Clin Transl Oncol. 2019;21(8):977–991.
   PubMed Web of Science ®Google Scholar
• Pushpakom S, Iorio F, Eyers P, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58.
   PubMed Web of Science ®Google Scholar
• de Groot AF, Appelman-Dijkstra NM, van der Burg SH, et al. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review. Cancer Treat Rev. 2018;62:18–28.
   PubMed Web of Science ®Google Scholar
• Renema N, Navet B, Heymann MF, et al. RANK-RANKL signalling in cancer. Biosci Rep. 2016;36(4):pii:e00366.
   PubMedGoogle Scholar
• Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008;29:155–192.
   PubMed Web of Science ®Google Scholar
• Wong BR, Josien R, Lee SY, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med. 1997;186(12):2075–2080.
   PubMed Web of Science ®Google Scholar
• Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nat. 1997;390(6656):175–179.
   Google Scholar
• Cheng ML, Fong L. Effects of RANKL-Targeted therapy in immunity and cancer. Front Oncol. 2014;3:329.
   PubMedGoogle Scholar
• Ahern E, Smyth MJ, Dougall WC, et al. Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy. Nat Rev Clin Oncol. 2018;15:676–693.
   PubMed Web of Science ®Google Scholar
• Zheng X, Turkowski K, Mora J, et al. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget. 2017;8(29):48436–48452.
   PubMedGoogle Scholar
• Chu GC, Chung LW. RANK-mediated signaling network and cancer metastasis. Cancer Metastasis Rev. 2014;33:497–509.
   PubMed Web of Science ®Google Scholar
• Esposito M, Kang Y. Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther. 2014;141:222–233.
   PubMed Web of Science ®Google Scholar
• Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014;14:611–622.
   PubMed Web of Science ®Google Scholar
• Odero-Marah VA, Wang R, Chu G, et al. Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res. 2008;18(8):858–870.
   PubMed Web of Science ®Google Scholar
• Yamada T, Tsuda M, Takahashi T, et al. RANKL expression speciically observed in vivo promotes epithelial mesenchymal transition and tumor progression. Am J Pathol. 2011;178(6):2845–2856.
   PubMed Web of Science ®Google Scholar
• Dufresne A, Derbel O, Cassier P, et al. Giant-cell tumor of bone, anti-RANKL therapy. Bonekey Rep. 2012;1:149.
   PubMedGoogle Scholar
• Yue Z, Yuan Z, Zeng L, et al. LGR4 modulates breast cancer initiation, metastasis, and cancer stem cells. Faseb J. 2018;32(5):2422–2437.
   PubMed Web of Science ®Google Scholar
• Accessed Mar 2020 https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/xgeva/xgeva_pi.pdf
   Google Scholar
• Infante M, Fabi A, Cognetti F, et al. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. J Exp Clin Cancer Res. 2019;38(1):12.
   PubMed Web of Science ®Google Scholar
• Deligiorgi MV, Panayiotidis MI, Trafalis DT. Combining immune checkpoint inhibitors with denosumab: a new era in repurposing denosumab in oncology? JBUON. 2020;25(1):1–14.
   Google Scholar
• Safety information for Xvega. Available from: https://www.xgeva.com/hcp/multiple-myeloma/renal-considerations. Accessed Mar 2020.
   Google Scholar
• Accessed Mar 2020. https://www.ema.europa.eu/en/documents/rmp-summary/xgeva-epar-risk-management-plan-summary_en.pdf
   Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Accessed Mar 2020. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
   Google Scholar
• Gnant M, Pfeiler G, Steger GG, et al. Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):339–351.
   PubMed Web of Science ®Google Scholar
• Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007;25(28):4431–4437.
   PubMed Web of Science ®Google Scholar
• Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res. 2008;14(20):6690–6696.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564–1571.
   PubMed Web of Science ®Google Scholar
• Body JJ, Lipton A, Gralow J, et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res. 2010;25(3):440–446.
   PubMed Web of Science ®Google Scholar
• Sun L, Yu S. Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis. Am J Clin Oncol. 2013;36(4):399–403.
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Toriz NH, et al. For the denosumab HALT prostate cancer study group C. denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–755.
   PubMed Web of Science ®Google Scholar
• Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082–3092.
   PubMed Web of Science ®Google Scholar
• Coleman R, Finkelstein DM, Barrios C, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(1):P62–70.
   Web of Science ®Google Scholar
• Body JJ, Bone HG, de Boer RH, et al. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer. 2015;51(13):1812–1821.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–822.
   PubMed Web of Science ®Google Scholar
• Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19:370–381.
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–5139.
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125–1132.
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Fizazi K, Body JJ, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016;24(1): 447–455.
   PubMed Web of Science ®Google Scholar
• Chen F, Pu F. Safety of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials. Oncol Res Treat. 2016;39(7–8):453–459.
   PubMed Web of Science ®Google Scholar
• Laskowski LK, Goldfarb DS, Howland MA, et al. A RANKL wrinkle: denosumab-induced hypocalcemia. J Med Toxicol. 2016;12(3):305–308.
   PubMed Web of Science ®Google Scholar
• Cooper MS, Gittoes NJ. Diagnosis and management of hypocalcaemia. BMJ. 2008;336(7656):1298–1302.
   PubMed Web of Science ®Google Scholar
• Nasser SM, Sahal A, Hamad A, et al. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: a retrospective cohort study. J Oncol Pharm Pract. 2019;25(8):1846–1852.
   PubMed Web of Science ®Google Scholar
• Body J, Bone HG, van Poznak C, et al. Risk factors for hypocalcemia in patients with cancer receiving denosumab. Ann Oncol. 2014;25:iv529.
   Web of Science ®Google Scholar
• Ishikawa K, Nagai T, Sakamoto K, et al. High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag. 2016;12:1831–1840.
   PubMed Web of Science ®Google Scholar
• Okada N, Kawazoe K, Teraoka K, et al. Identification of the risk factors associated with hypocalcemia induced by denosumab. Biol Pharm Bull. 2013;36(10):1622–1626.
   PubMed Web of Science ®Google Scholar
• Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs. 2010;24(1):23–39.
   PubMed Web of Science ®Google Scholar
• Watkins KR, Rogers JE, Atkinson B. Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency. Support Care Cancer. 2015;23(6):1657–1662.
   PubMed Web of Science ®Google Scholar
• Block GA, Bone HG, Fang L, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012 Jul;27(7):1471–1479.
   PubMed Web of Science ®Google Scholar
• Thongprayoon C, Acharya P, Acharya C, et al. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. Osteoporos Int. 2018;29(8):1737–1745.
   PubMed Web of Science ®Google Scholar
• Jalleh R, Basu G, Le Leu R, et al. Denosumab-induced severe hypocalcaemia in chronic kidney disease. Case Rep Nephrol. 2018;2018:7384763.
   PubMedGoogle Scholar
• Denosumab product information. Australia (NSW): amgen Australia, 2018 [revised 2018 Jul18]. Accessed Mar 2020. Available from: http://www.guildlink.com.au/gc/ws/amgen/pi.cfm?product=anpprolm10315
   Google Scholar
• Chen CL, Chen NC, Hsu CY, et al. An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab. 2014;99(7):2426–2432.
   PubMed Web of Science ®Google Scholar
• Prescribing information for PROLIA. Accessed Apr 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125320s186lbl.pdf
   Google Scholar
• Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–1117.
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw – 2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–1956.
   PubMed Web of Science ®Google Scholar
• Khan AA, Morrison A, Hanley DA, et al. International task force on osteonecrosis of the jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23.
   PubMed Web of Science ®Google Scholar
• Lombard T, Neirinckx V, Rogister B, et al. Medication-related osteonecrosis of the jaw: new insights into molecular mechanisms and cellular therapeutic approaches. Stem Cells Int. 2016;2016:8768162.
   PubMed Web of Science ®Google Scholar
• Nifosì AF, Zuccarello M, Nifosì L, et al. Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology. J Korean Assoc Oral Maxillofac Surg. 2019;45(1):3–8.
   PubMed Web of Science ®Google Scholar
• Di Fede O, Panzarella V, Mauceri R, et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int. 2018;2018:2684924.
   PubMed Web of Science ®Google Scholar
• Kyrgidis A, Toulis KA. Denosumab-related osteonecrosis of the jaws. Osteoporos Int. 2011;22(1):369–370.
   PubMed Web of Science ®Google Scholar
• Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14(9):901–908.
   PubMed Web of Science ®Google Scholar
• Qi WX, Tang LN, He AN, et al. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014;19(2):403–410.
   PubMed Web of Science ®Google Scholar
• Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23(5):1341.
   PubMed Web of Science ®Google Scholar
• Peddi P, Lopez-Olivo MA, Pratt GF, et al. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev. 2013;39(1):97–104.
   PubMed Web of Science ®Google Scholar
• Lipton A, Saad F, Van Poznak CH, et al. Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: results from three phase III trials (abstract). J Clin Oncol. 2013;31:(suppl; abstr 9640).
   Web of Science ®Google Scholar
• Egloff-Juras C, Gallois A, Salleron J, et al. Denosumab-related osteonecrosis of the jaw: a retrospective study. J Oral Pathol Med. 2018;47(1):66–70.
   PubMed Web of Science ®Google Scholar
• Yoshimura H, Ohba S, Yoshida H, et al. Denosumab-related osteonecrosis of the jaw in a patient with bone metastases of prostate cancer: a case report and literature review. Oncol Lett. 2017;14(1):127–136.
   PubMed Web of Science ®Google Scholar
• Corraini P, Heide-Jørgensen U, Schiødt M, et al. Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark. Cancer Med. 2017;6(10):2271–2277.
   PubMed Web of Science ®Google Scholar
• Svejda B, Muschitz C, Gruber R, et al. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)]. Wien Med Wochenschr. 2016;166(1–2):68–74.
   PubMed Web of Science ®Google Scholar
• Accessed 2020 Oct 5.https://www.ema.europa.eu/en/documents/product-information/forsteo-epar-product-information_en.pdf.
   Google Scholar
• Soydan SS, Uckan S. Management of bisphosphonate-related osteonecrosis of the jaw with a platelet-rich fibrin membrane: technical report. J Oral Maxillofac Surg. 2014;72(2):322–326.
   PubMed Web of Science ®Google Scholar
• Hayashida S, Soutome S, Yanamoto S, et al. Evaluation of the treatment strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the factors affecting treatment outcome: a multicenter retrospective study with propensity score matching analysis. J Bone Miner Res. 2017;32(10):2022–2029.
   PubMed Web of Science ®Google Scholar
• Rupel K, Ottaviani G, Gobbo M, et al. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol. 2014;50(11):1049–1057.
   PubMed Web of Science ®Google Scholar
• Merigo E, Cella L, Oppici A, et al. Combined approach to treat medication-related osteonecrosis of the jaws. J Lasers Med Sci. 2018;9(2):92–100.
   PubMed Web of Science ®Google Scholar
• Mauceri R, Panzarella V, Pizzo G. Platelet-Rich Plasma (PRP) in dental extraction of patients at risk of bisphosphonate-related osteonecrosis of the jaws: a two-year longitudinal study. Appl Sci. 2020;10(13):4487.
   Google Scholar
• Xgeva [summary of product characteristics]. Accessed Mar 2020. Available from: https://www.ema.europa.eu/en/documents/product-information/xgeva-epar-product-information_en.pdf
   Google Scholar
• Ottesen C, Schiodt M, Gotfredsen K. Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): a systematic review. Heliyon. 2020;6(4):e03795.
   PubMed Web of Science ®Google Scholar
• Anesi A, Generali L, Sandoni L, et al. From osteoclast differentiation to osteonecrosis of the jaw: molecular and clinical insights. Int J Mol Sci. 2019;20(19):pii:E4925.
   PubMed Web of Science ®Google Scholar
• Fung PL, Nicoletti P, Shen Y, et al. Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Oral Maxillofac Surg Clin North Am. 2015;27(4):537–546.
   PubMed Web of Science ®Google Scholar
• Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23.
   PubMed Web of Science ®Google Scholar
• Khow KS, Shibu P, Yu SC, et al. Epidemiology and postoperative outcomes of atypical femoral fractures in older adults: a systematic review. J Nutr Health Aging. 2017;21(1):83–91.
   PubMed Web of Science ®Google Scholar
• Lim SJ, Yeo I, Yoon PW, et al. Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study. Osteoporos Int. 2018;29(11):2427–2435.
   PubMed Web of Science ®Google Scholar
• Eisenstein N, Kasavkar G, Bhavsar D, et al. Incidence and medical management of bisphosphonate-associated atypical femoral fractures in a major trauma centre: a retrospective observational study. BMC Musculoskelet Disord. 2017;18(1):29.
   PubMedGoogle Scholar
• Drampalos E, Skarpas G, Barbounakis N, et al. Atypical femoral fractures bilaterally in a patient receiving denosumab. Acta Orthop. 2014;85(1):3–5.
   PubMed Web of Science ®Google Scholar
• Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98(11):4483–4492.
   PubMed Web of Science ®Google Scholar
• Adler RA. MANAGEMENT OF ENDOCRINE DISEASE: atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy. Eur J Endocrinol. 2018;178(3):R81–7.
   PubMedGoogle Scholar
• Khow KS, Yong TY. Atypical femoral fracture in a patient treated with denosumab. J Bone Miner Metab. 2015;33(3):355–358.
   PubMed Web of Science ®Google Scholar
• Schilcher J, Aspenberg P. Atypical fracture of the femur in a patient using denosumab–a case report. Acta Orthop. 2014;85(1):6–7.
   PubMed Web of Science ®Google Scholar
• Thompson RN, Armstrong CL, Heyburn G. Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report. Bone. 2014;61:44–47.
   PubMed Web of Science ®Google Scholar
• Selga J, Nuñez JH, Minguell J, et al. Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review. Osteoporos Int. 2016;27(2): 827–832.
   PubMed Web of Science ®Google Scholar
• Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–523.
   PubMed Web of Science ®Google Scholar
• Henry D, Vadhan-Raj S, Hirsh V, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014;22(3):679–687.
   PubMed Web of Science ®Google Scholar
• Martin M, Bell R, Bourgeois H, et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res. 2012;18(17):4841–4849.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012;7(12):1823–1829.
   PubMed Web of Science ®Google Scholar
• Yang SP, Kim TW, Boland PJ, et al. A retrospective review of atypical femoral fracture in metastatic Bone disease patients receiving Denosumab therapy. Oncologist. 2017;22(4):438–444.
   PubMed Web of Science ®Google Scholar
• Austin DC, Torchia MT, Klare CM, et al. Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab. Acta Orthop. 2017;88(3):351–353.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Ozaki Y, Kizawa R, et al. Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. BMC Cancer. 2019;19(1):980.
   PubMed Web of Science ®Google Scholar
• Tateiwa D, Outani H, Iwasa S, et al. Atypical femoral fracture associated with bone-modifying agent for bone metastasis of breast cancer: a report of two cases. J Orthop Surg (Hong Kong). 2017;25(3):2309499017727916.
   Google Scholar
• Villiers J, Clark DW, Jeswani T, et al. An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab. Case Rep Rheumatol. 2013;2013:249872.
   PubMedGoogle Scholar
• Donnelly E, Meredith DS, Nguyen JT, et al. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res. 2012;27:672–678.
   PubMed Web of Science ®Google Scholar
• Lloyd AA, Gludovatz B, Riedel C, et al. Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. Proc Natl Acad Sci USA. 2017;114(33):8722–8727.
   PubMed Web of Science ®Google Scholar
• Güerri-Fernández RC, Nogués X, Quesada Gómez JM, et al. Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. J Bone Miner Res. 2013;28(1):162–168.
   PubMed Web of Science ®Google Scholar
• Lee SH, Lee YH, Suh JS. Lateral cortical thickening and bone heterogeneity of the subtrochanteric femur measured with quantitative CT as indicators for early detection of atypical femoral fractures in long-term bisphosphonate users. AJR Am J Roentgenol. 2017;209(4):867–873.
   PubMed Web of Science ®Google Scholar
• Koeppen VA, Schilcher J, Aspenberg P. Atypical fractures do not have a thicker cortex. Osteoporos Int. 2012;23:2893–2896.
   PubMed Web of Science ®Google Scholar
• Schilcher J, Sandberg O, Isaksson H, et al. Histology of 8 atypical femoral fractures: remodeling but no healing. Acta Orthop. 2014 Jun;85(3):280–286.
   PubMed Web of Science ®Google Scholar
• Roca-Ayats N, Balcells S, Garcia-Giralt N, et al. GGPS1 mutation and atypical femoral fractures with bisphosphonates. N Engl J Med. 2017;376(18):1794–1795.
   PubMed Web of Science ®Google Scholar
• Koh A, Guerado E, Giannoudis PV. Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management. Bone Joint J. 2017;99-B(3):295–302.
   PubMedGoogle Scholar
• Khosla S, Cauley JA, Compston J, et al. Addressing the crisis in the treatment of osteoporosis: a path forward. J Bone Miner Res. 2016;32(3):424–430.
   PubMed Web of Science ®Google Scholar
• Toro G, Ojeda-Thies C, Calabrò G, et al. Management of atypical femoral fracture: a scoping review and comprehensive algorithm. BMC Musculoskelet Disord. 2016;17:227.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, et al. Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors. Breast Cancer Res Treat. 2020;179(1):153–159.
   PubMed Web of Science ®Google Scholar
• Popp AW, Zysset PK, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int. 2016;27(5):1917–1921.
   PubMed Web of Science ®Google Scholar
• Tripto-Shkolnik L, Fund N, Rouach V, et al. Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider. Bone. 2020;130:115150.
   PubMed Web of Science ®Google Scholar
• Anastasilakis AD, Polyzos SA, Makras P, et al. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 2017;32(6): 1291–1296.
   PubMed Web of Science ®Google Scholar
• McClung MR. Cancel the denosumab holiday. Osteoporos Int. 2016;27:1677–1682.
   PubMed Web of Science ®Google Scholar
• Brown JP, Roux C, Törring O, et al. Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res. 2013;28(4):746–752.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of Denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190–198.
   PubMed Web of Science ®Google Scholar
• Lamy O, Stoll D, Aubry-Rozier B, et al. Stopping denosumab. Curr Osteoporos Rep. 2019;17(1):8–15.
   PubMed Web of Science ®Google Scholar
• Anastasilakis AD, Papapoulos SE, Polyzos SA, et al. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2‐year clinical trial. J Bone Miner Res. 2019;34:2220–2228.
   PubMed Web of Science ®Google Scholar
• Graber J, Reichenbach S, Ziswiler HR, et al. A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J Bone Miner Res. 2020;35:1207–1215.
   PubMed Web of Science ®Google Scholar
• Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315–323.
   PubMed Web of Science ®Google Scholar
• Stolina M, Dwyer D, Ominsky MS, et al. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J Immunol. 2007;179(11):7497–7505.
   PubMed Web of Science ®Google Scholar
• Miller RE, Branstetter D, Armstrong A, et al. Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J Immunol. 2007;179(1):266–274.
   PubMed Web of Science ®Google Scholar
• Stolina M, Schett G, Dwyer D, et al. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapies. Arthritis Res Ther. 2009;11(6):R187.
   PubMed Web of Science ®Google Scholar
• Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875–4882.
   PubMed Web of Science ®Google Scholar
• Ferrari-Lacraz S, Ferrari S. Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int. 2011;22(2):435–446.
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765.
   PubMed Web of Science ®Google Scholar
• Watts NB, Roux C, Modlin JF, et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int. 2012;23:327–337.
   PubMed Web of Science ®Google Scholar
• Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153–161.
   PubMed Web of Science ®Google Scholar
• Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43:222–229.
   PubMed Web of Science ®Google Scholar
• Golden W, Crittenden D, Uhart M, et al. AB0908 findings from denosumab (Prolia®) mgrPostmarketing safety surveillance for serious infections: table 1. Ann Rheum Dis. 2015;74(Suppl2): 1204.1–1204.
   Google Scholar
• Yanbeiy ZA, Hansen KE. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. Drug Des Devel Ther. 2019;13:2843–2852.
   PubMed Web of Science ®Google Scholar
• Pufall MA. Glucocorticoids and cancer. Adv Exp Med Biol. 2015;872:315–333.
   PubMed Web of Science ®Google Scholar
• Chandran T, Venkatachalam I. Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review. Singapore Med J. 2019;60(7):364–378.
   PubMed Web of Science ®Google Scholar
• Lyu H, Jundi B, Xu C, et al. Comparison of denosumab and bisphosphonates in patients with osteoporosis: a meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2019;104(5):1753–1765.
   PubMed Web of Science ®Google Scholar
• von Keyserlingk C, Hopkins R, Anastasilakis A, et al. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis. Semin Arthritis Rheum. 2011;41(2):178–186.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho LY, Ma KM. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone. 2015;75:222–228.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xie F, Yun H, et al. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab. Arthritis Rheumatol. 2015;67(6):1456–1464.
   PubMed Web of Science ®Google Scholar
• Bonani M, Frey D, de Rougemont O, et al. Infections in De Novo kidney transplant recipients treated with the RANKL inhibitor denosumab. Transplantation. 2017;101(9):2139–2145.
   PubMed Web of Science ®Google Scholar
• Brunova J, Kratochvilova S, Stepankova J. Osteoporosis therapy with denosumab in organ transplant recipients. Front Endocrinol (Lausanne). 2018;9:162.
   PubMed Web of Science ®Google Scholar
• Tsukamoto S, Righi A, Vanel D, et al. Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab. Jpn J Clin Oncol. 2017;47(11):1090–1096.
   PubMed Web of Science ®Google Scholar
• Abo Loha C, Livio F. Pharmacovigilance update. Rev Med Suisse. 2019;15:92–95.
   PubMedGoogle Scholar
• Tovazzi V, Dalla Volta A, Pedersini R, et al. Excess of second tumors in denosumab-treated patients: a metabolic hypothesis. Future Oncol. 2019;15(20): 2319–2321.
   PubMed Web of Science ®Google Scholar
• Li S, Dong Y, Wang K, et al. Transcriptomic analyses reveal the underlying pro-malignant functions of PTHR1 for osteosarcoma via activation of Wnt and angiogenesis pathways. J Orthop Surg Res. 2017;12(1):68.
   PubMedGoogle Scholar
• Timotheadou E, Kalogeras KT, Koliou GA, et al. Evaluation of the prognostic value of RANK, OPG, and RANKL mRNA expression in early breast cancer patients treated with anthracycline-based adjuvant chemotherapy. Transl Oncol. 2017;10(4):589–598.
   PubMed Web of Science ®Google Scholar
• Owen S, Ye L, Sanders AJ, et al. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Res. 2013;33(1):199–206.
   PubMed Web of Science ®Google Scholar
• Bhatia P, Sanders MM, Hansen MF. Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res. 2005;11:162–165.
   PubMed Web of Science ®Google Scholar
• Park HS, Lee A, Chae BJ, et al. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer. J Surg Oncol. 2014;110:807–812.
   PubMed Web of Science ®Google Scholar
• Papanastasiou AD, Sirinian C, Kalofonos HP. Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration. Breast Cancer Res. 2012;14:R112. .
   PubMed Web of Science ®Google Scholar
• Camacho PM, Petak SM, Binkley N, et al. American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis- 2020 update executive summary. Endocr Pract. 2020;26(5):564–570.
   PubMed Web of Science ®Google Scholar
• Anne Sophie Sølling AS, Harsløf T, Langdahl B. Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Miner Res. 2020;35(10):1858–1870.
   PubMed Web of Science ®Google Scholar
• Accessed Apr 2020. http://clinicaltrials.gov
   Google Scholar
• Accessed Apr 2020. https://courses.washington.edu/bonephys/denosumab/Rothstein%20FDA%20deno%20safety.pdf
   Google Scholar
• Polyzos SA, Makras P, Tournis S, et al. Off-label uses of denosumab in metabolic bone diseases. Bone. 2019;129:115048.
   PubMed Web of Science ®Google Scholar